Aim: Development of EGF-liposomes (LP-EGF) for selective molecules delivery in tumors expressing EGFR.
Material & methods: In vitro cellular interaction of EGF-LP and nontargeted liposomes (LP-N) was assayed at 37 and 4°C in cells expressing different EGFR levels. Receptor-mediated uptake was investigated by competition with a monoclonal antibody anti-EGFR. Selective intracellular drug delivery and efficacy was tested by oxaliplatin encapsulation. In vivo biodistribution of LP-N and LP-EGF was done in xenograft model.
Results: LP-EGF was internalized by an active and selective mechanism through EGFR without receptor activation. Oxaliplatin LP-EGF decreased IC50 between 48 and 13% in cell EGFR+. LP-EGF was accumulated in tumor over 72 h postdosing, while LP-N in spleen.
Conclusion: LP-EGF represents an attractive nanosystem for cancer therapy or diagnosis.

cetuximab, colorectal cancer, EGF, EGFR, oxaliplatin, targeted liposomes,
No subscription
Department of Surgery

Zalba, S, Contreras, A.M, Merino, M, Navarro, I, De Ilarduya, C.T, Trocóniz, I.F, … Garrido, M.J. (2016). EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model. Nanomedicine, 11(5), 465–477. doi:10.2217/nnm.15.208